3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
5
Terminated
1
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Conditions
Hematologic Neoplasms
4
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Myelodysplastic Syndromes
3
Leukemia, Myeloid, Acute
3
beta-Thalassemia
2
Multiple Myeloma
2
Lymphoma, Non-Hodgkin
2
Hodgkin Disease
2
Graft vs Host Disease
2
Anemia, Refractory, with Excess of Blasts
2
Virus Diseases
1
Thalassemia
1
Primary Myelofibrosis
1
Non-Malignant Neoplasm
1
Neurofibromatosis 1
1
Neoplasm, Residual
1
Myeloproliferative Disorders
1
Leukemia, Myelomonocytic, Juvenile
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia, B-Cell
1
Influenza, Human
1
Fanconi Anemia
1
Cytopenia
1
Chromosome Aberrations
1
Chromosome 7, monosomy
1
Anemia, Sickle Cell
1
Interventions
Cyclophosphamide
11
Azacitidine
10
fludarabine
9
Whole-Body Irradiation
9
Specimen Handling
9
Biopsy
9
Stem Cell Transplantation
8
Mycophenolic Acid
8
venetoclax
7
fludarabine phosphate
7
Tacrolimus
6
Cytarabine
6
X-Rays
5
Hematopoietic Stem Cell Transplantation
5
Decitabine
4
Cyclosporine
4
Thiotepa
3
Peripheral Blood Stem Cell Transplantation
3
Melphalan
3
Magnetic Resonance Spectroscopy
3
Injections
3
Idarubicin
3
Granulocyte Colony-Stimulating Factor
3
Filgrastim
3
Cyclosporins
3
Busulfan
3
11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene
3
ruxolitinib
2
pegylated granulocyte colony-stimulating factor
2
olutasidenib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Leukemia, Myelomonocytic, Chronic
×
thymoglobulin
×
Clear all
NCT04888741
2026-05-05
MoTD
University of Birmingham
Phase 2
Recruiting
400 enrolled